Acadian Asset Management
CRDL

Acadian Asset Management’s Cardiol Therapeutics CRDL Stock Holding History

Acadian Asset Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45K Buy
+44,255
New +$56K ﹤0.01% 1861

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Acadian Asset Management's CRDL Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Cardiol Therapeutics (CRDL) in Q2 2026: 44,255 shares worth $45K. The stake represents ﹤0.01% of the portfolio and ranks #1861 among its holdings.

52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Acadian Asset Management held 44,255 shares of Cardiol Therapeutics worth $45K as of Q2 2026.
  • Cardiol Therapeutics was a new Acadian Asset Management position in Q2 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1861 holding.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.